- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Surgical instruments.
Displaying page 1 of 2.
EudraCT Number: 2016-004129-18 | Sponsor Protocol Number: AK581 | Start Date*: 2017-03-17 | ||||||||||||||||
Sponsor Name:Akari Therapeutics Plc | ||||||||||||||||||
Full Title: CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | ||||||||||||||||||
Medical condition: Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) LT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-010173-20 | Sponsor Protocol Number: A3051113 | Start Date*: 2009-08-06 | |||||||||||
Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | |||||||||||||
Full Title: A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY | |||||||||||||
Medical condition: Smoking cessation in patients scheduled for elective surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001581-20 | Sponsor Protocol Number: IRRB/72/14 | Start Date*: 2018-02-08 | |||||||||||||||||||||
Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT | |||||||||||||||||||||||
Full Title: THE ADDITION OF SIMVASTATIN ADMINISTRATION TO COLD STORAGE SOLUTION OF EXPLANTED WHOLE LIVER GRAFTS FOR FACING ISCHEMIA/REPERFUSION INJURY IN AN AREA WITH LOW RATE OF DECEASED DONATION. A MONOCENT... | |||||||||||||||||||||||
Medical condition: ISCHEMIC REPERFUSION INJURY AFTER LIVER TRANSPLANTATION: HEPATIC ISCHEMIA AND REPERFUSION INJURY REPRESENTS THE MAIN UNDERLYING MECHANISM FOR GRAFT DYSFUNCTION, AND FAILURE, POST-TRANSPLANTATION. H... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001871-31 | Sponsor Protocol Number: 4076 | Start Date*: 2008-09-04 | ||||||||||||||||
Sponsor Name:Region skåne- Hässleholms sjukvårdsorganisation | ||||||||||||||||||
Full Title: Local steroid injection in the treatment of idiopathic carpal tunnel syndrome: A randomized double-blind placebo-controlled trial among patients planned for surgical treatment | ||||||||||||||||||
Medical condition: Neurography verified Carpal tunnel syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005426-19 | Sponsor Protocol Number: 51237 | Start Date*: 2016-02-09 | |||||||||||
Sponsor Name:Rigshospitalet, Copenhagen University Hospitals | |||||||||||||
Full Title: "Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia in Patients following Recovery from Impacted Mandibular Third Molar Extraction. A Randomized, Placebo-controlled, ... | |||||||||||||
Medical condition: Healthy volunteers (n = 94) are included. The main study includes 14 subjects who have had an uncomplicated, impacted mandibular, third molar extraction 4-5 weeks prior to participation in the stud... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002338-21 | Sponsor Protocol Number: A4250-005 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Albireo AB | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1) | |||||||||||||
Medical condition: Progressive Familial Intrahepatic Cholestasis Types 1 and 2 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) GB (Completed) NL (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000781-38 | Sponsor Protocol Number: PHAO2011/LB/LIZ-BONE | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Direction de la recherche clinique du centre hospitalier universitaire de Tours, Bretonneau | |||||||||||||
Full Title: Prospective, Randomized, open label, European, multicenter study of the efficacy of the linezolid-rifampin combination versus standard of care in the treatment of Gram-positive prosthetic hip joint... | |||||||||||||
Medical condition: Hip prosthesis infected by gram-positive bacteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000148-14 | Sponsor Protocol Number: PLX108-10 | Start Date*: 2015-06-03 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN | |||||||||||||
Medical condition: Pigmented villonodular synovitis (PVNS) / giant cell tumour of tendon sheath (GCT-TS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Temporarily Halted) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005241-38 | Sponsor Protocol Number: LX6171.1-201-AAMI | Start Date*: 2007-11-12 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) ... | |||||||||||||
Medical condition: Age-Associated Memory Impairment (AAMI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000188-25 | Sponsor Protocol Number: LoveMi | Start Date*: 2013-10-23 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Lormetazepam versus Midazolam used as sedatives for critically ill patients. | ||
Medical condition: Sedation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004034-29 | Sponsor Protocol Number: A206T-G01-001 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||
Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi... | |||||||||||||
Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002964-29 | Sponsor Protocol Number: IMMU-132-13 | Start Date*: 2021-10-12 | ||||||||||||||||||||||||||
Sponsor Name:Gilead Sciences Inc | ||||||||||||||||||||||||||||
Full Title: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer | ||||||||||||||||||||||||||||
Medical condition: Metastatic or Locally Advanced Unresectable Urothelial Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Trial now transitioned) FR (Trial now transitioned) PT (Completed) BE (Trial now transitioned) AT (Ongoing) IT (Trial now transitioned) IE (Trial now transitioned) HU (Completed) BG (Completed) CZ (Completed) HR (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005199-27 | Sponsor Protocol Number: E7080-G000-211 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eisai Ltd. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W... | |||||||||||||
Medical condition: 131I-refractory differentiated thyroid cancer (DTC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003153-18 | Sponsor Protocol Number: IMCgp100-202 | Start Date*: 2017-08-25 | |||||||||||
Sponsor Name:Immunocore Limited | |||||||||||||
Full Title: A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced U... | |||||||||||||
Medical condition: Uveal Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Trial now transitioned) NL (Completed) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003832-54 | Sponsor Protocol Number: LUM001-303 | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Mirum Pharmaceuticals, Inc. | |||||||||||||
Full Title: A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATME... | |||||||||||||
Medical condition: Alagille syndrome (ALGS). This is an example of cholestatic liver disease in children. In patients with Alagille syndrome, impairment of the egress of bile acids from the liver leads to cholestasis... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005229-95 | Sponsor Protocol Number: PBKR03-001 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Passage Bio, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Dis... | |||||||||||||
Medical condition: Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive lysosomal storage disease (LSD) caused by mutations in the gene encoding the hydrolytic enzyme galactosylceramidase (galactoce... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002096-18 | Sponsor Protocol Number: B2151007 | Start Date*: 2014-08-13 | |||||||||||
Sponsor Name:Pfizer Inc.,235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF05212384 PLUS 5-FLUOROURACIL-LEUCOVORIN-IRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER | |||||||||||||
Medical condition: Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000430-11 | Sponsor Protocol Number: RFBU11-I | Start Date*: 2011-10-06 | |||||||||||
Sponsor Name:G.I.S.E. - SOCIETA'' ITALIANA CARDIOLOGIA INVASIVA | |||||||||||||
Full Title: Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX) | |||||||||||||
Medical condition: Real world ACS both Non-ST segment elevation and ST-segment elevation patients undergoing coronary angiography±PCI. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) NL (Ongoing) SE (Ongoing) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011850-17 | Sponsor Protocol Number: H6D-EW-LVIK | Start Date*: 2009-10-23 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company Limited | ||||||||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for... | ||||||||||||||||||
Medical condition: Erectile dysfunction following Bilateral Nerve-Sparing Radical Prostatectomy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) PL (Completed) BE (Completed) GB (Completed) IT (Completed) PT (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003973-23 | Sponsor Protocol Number: 213831 | Start Date*: 2021-06-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd. | |||||||||||||
Full Title: A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Mole... | |||||||||||||
Medical condition: Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) IE (Completed) PL (Trial now transitioned) NL (Trial now transitioned) FI (Completed) FR (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended) ES (Ongoing) HU (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
